Lupus Nephritis

Voclosporin Granted Priority Review for Lupus Nephritis

Publish Date July 27, 2020

The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.

Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis

Publish Date June 24, 2020

Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.

Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses

Publish Date June 9, 2020

Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.

Voclosporin NDA for Lupus Nephritis Submitted to FDA

Publish Date May 28, 2020

The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.

Updated EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis

Publish Date May 5, 2020

The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.

FDA: Studies Underway to Evaluate Chloroquine for COVID-19

Publish Date March 23, 2020

The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).

Antimalarials May Cut Risk for Type 2 Diabetes in Lupus Patients

Publish Date March 5, 2020

T2DM risk reduced by 39 percent for those with high adherence to antimalarial therapy for managing lupus.

Low Income May Increase Risk for Specific Glomerular Diseases

Publish Date February 25, 2020

Lower income associated with higher incidence of lupus nephritis, ANCA-related glomerulonephritis.

Renal Arteriosclerosis Develops Prematurely in Lupus Nephritis

Publish Date January 13, 2020

A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.

Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial

Publish Date December 25, 2019

GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.